Should You Buy Astrana Health Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Astrana Health Inc. (ASTH) scores a robust 7.5/10 on our 32-signal Quality of Company framework. At the current market price of $44.55, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 2 of 12 CirclFi valuation models project upside for Astrana Health Inc. (ASTH) at $44.55 — the model consensus leans bearish, with a Quality Score of 7.5/10 and Value-Trap risk of 32/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $55.14 (+23.8% upside)
- According to the CirclFi Quality of Company (QOC) framework, Astrana Health Inc.'s score of 7.5/10 reflects durable competitive advantages that should sustain earnings power through market cycles.
- According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $55.14 (+23.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
The Bear Case
Target: $1.05 (-97.6%)
- According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $1.05 (-97.6%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +121.4% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
The Bottom Line
Our valuation engine sends a clear cautionary signal on Astrana Health Inc. at $44.55. 10/12 models flag overvaluation, composite fair value sits at $18.83 (-57.7%), and the risk-reward profile appears unfavorable. Quality at 7.5/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Astrana Health Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy ASTH stock right now?
Based on CirclFi's multi-model analysis, 2 of 12 models see upside for ASTH at $44.55. The models are divided, which means the investment case depends heavily on your assumptions about Astrana Health Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Astrana Health Inc.?
Key risks include: wide model disagreement (5165% spread), signaling high uncertainty; general market and sector-specific risks affecting Services-Management Consulting Services companies. Always diversify and consult a financial advisor.
How does ASTH compare to its competitors?
Among Services-Management Consulting Services peers, ASTH holds a Quality Score of 7.5/10. Comparable companies include BAH (QOC 10.0), G (QOC 10.0), HURN (QOC 9.2). The relative ranking helps investors identify whether ASTH offers better fundamental quality than alternatives in the same sector.
Is ASTH a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ASTH's Quality Score of 7.5/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy ASTH at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $1.05 to $55.14. At $44.55, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ASTH.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad